Limits...
Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.

Ichikawa S, Fukuhara N, Katsushima H, Takahashi T, Yamamoto J, Yokoyama H, Sasaki O, Fukuhara O, Nomura J, Ishizawa K, Ichinohasama R, Muto A, Igarashi K, Harigae H - Cancer Sci. (2014)

Bottom Line: BACH2, a B cell-specific transcriptional repressor, plays a significant role in B cell maturation.There were no significant differences between the two groups with regard to clinical characteristics and outcomes.In cases with high BACH2 expression in GCB and non-GCB groups, the 3-year overall survival (OS) rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256).

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Show MeSH

Related in: MedlinePlus

Survival analyses of the patients among germinal center B cell phenotype (GCB) and non-GCB groups. (a,b) Overall survival (a) and progression-free survival (b) of each group. (c,d) Overall survival (c) and progression-free survival (d) according to BACH2 expression levels.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317811&req=5

fig02: Survival analyses of the patients among germinal center B cell phenotype (GCB) and non-GCB groups. (a,b) Overall survival (a) and progression-free survival (b) of each group. (c,d) Overall survival (c) and progression-free survival (d) according to BACH2 expression levels.

Mentions: All patients were treated with rituximab-containing chemotherapy (Table 1). Overall treatment response was good and resulted in a 3-year OS rate of 80.8% and a 3-year PFS rate of 71.0%. After three years following diagnosis, there were no cases of relapse or death from any causes. Survival outcome is shown in Table 1 and Figure 2. There were no differences in survival outcome; however, more relapsed cases were confirmed in the non-GCB group, which could result in relatively short PFS. In cases with high BACH2-expression, 3-year OS rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256). The 3-year PFS was also shorter than that with low expression, although it was not significant (62.5% vs 80.3%, P = 0.0681).


Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.

Ichikawa S, Fukuhara N, Katsushima H, Takahashi T, Yamamoto J, Yokoyama H, Sasaki O, Fukuhara O, Nomura J, Ishizawa K, Ichinohasama R, Muto A, Igarashi K, Harigae H - Cancer Sci. (2014)

Survival analyses of the patients among germinal center B cell phenotype (GCB) and non-GCB groups. (a,b) Overall survival (a) and progression-free survival (b) of each group. (c,d) Overall survival (c) and progression-free survival (d) according to BACH2 expression levels.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317811&req=5

fig02: Survival analyses of the patients among germinal center B cell phenotype (GCB) and non-GCB groups. (a,b) Overall survival (a) and progression-free survival (b) of each group. (c,d) Overall survival (c) and progression-free survival (d) according to BACH2 expression levels.
Mentions: All patients were treated with rituximab-containing chemotherapy (Table 1). Overall treatment response was good and resulted in a 3-year OS rate of 80.8% and a 3-year PFS rate of 71.0%. After three years following diagnosis, there were no cases of relapse or death from any causes. Survival outcome is shown in Table 1 and Figure 2. There were no differences in survival outcome; however, more relapsed cases were confirmed in the non-GCB group, which could result in relatively short PFS. In cases with high BACH2-expression, 3-year OS rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256). The 3-year PFS was also shorter than that with low expression, although it was not significant (62.5% vs 80.3%, P = 0.0681).

Bottom Line: BACH2, a B cell-specific transcriptional repressor, plays a significant role in B cell maturation.There were no significant differences between the two groups with regard to clinical characteristics and outcomes.In cases with high BACH2 expression in GCB and non-GCB groups, the 3-year overall survival (OS) rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256).

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Show MeSH
Related in: MedlinePlus